Brand names: Pravastatin Sodium
4 interactions on record
Other macrolides (e.g., erythromycin and azithromycin) have the potential to increase statin exposures while used in combination. Other macrolides (e.g., erythromycin and azithromycin) have the potential to increase statin exposures while used in combination.
Source: FDA drug label - pravastatin sodium
(2.6, 7.1) Clarithromycin: combination increases exposure. 7.2 Clarithromycin and Other Macrolide Antibiotics The risk of myopathy/rhabdomyolysis is increased with concomitant administration of clarithromycin. Limit pravastatin to 40 mg once daily for concomitant use with clarithromycin [see Dosage and Administration (2.7) , Warnings and Precautions (5.1) , and Clinical Pharmacology (12.3) ].
Source: FDA drug label - pravastatin sodium
7 DRUG INTERACTIONS For the concurrent therapy of either cyclosporine, fibrates, niacin (nicotinic acid), or erythromycin, the risk of myopathy increases [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3) ]. Other macrolides (e.g., erythromycin and azithromycin) have the potential to increase statin exposures while used in combination. Other macrolides (e.g., erythromycin and azithromycin) have the potential to increase statin exposures while used in combination.
Source: FDA drug label - pravastatin sodium
7 DRUG INTERACTIONS See full prescribing information for details regarding concomitant use of pravastatin sodium tablets with other drugs that increase the risk of myopathy and rhabdomyolysis. ( 2.5 , 7.1 ) Bile Acid Sequestrants: in patients taking a bile acid sequestrant, administer pravastatin sodium tablets at least 1 hour before or at least 4 hours after the bile acid sequestrant ( 7.2 ) 7.1 Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with Pravastatin Pravastatin is a substrate of the transport protein OATP1B1. Pravastatin plasma levels can be significantly increased with concomitant administration of inhibitors of OATP1B1.
Source: FDA drug label - pravastatin sodium